Elkashef Kholoud A, Abdel Fattah Nelly R, Mesbah Noha M, El-Shaarawy Fatma F, Amer Mahmoud, Fakhr Ahmed Elsadek, Gharib Amal F, Abo-Elmatty Dina M, Abdel-Hamed Asmaa R
Department of Biochemistry, Faculty of Pharmacy, Sinai University, El-Arish, Egypt.
Department of Psychiatry, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Int J Health Sci (Qassim). 2025 Jan-Feb;19(1):22-30.
This study aims to determine the prevalence of Occult Hepatitis B and C Infections among Egyptian injection drug users (IDUs) and identify key risk factors contributing to their occurrence within this high-risk group.
In this cross-sectional study, 200 Egyptian IDUs were assessed. Participants were negative for Hepatitis B surface antigen and hepatitis C virus (HCV) RNA, with anti-HCV positive patients who achieved sustained virologic response after treatment included. Quantitative polymerase chain reaction (PCR) was used to detect HCV RNA in plasma and peripheral blood mononuclear cells, while HBV DNA was identified via nested PCR. Comparisons were made between Occult Hepatitis B infection (OBI) positive and OBI negative subgroups, as well as between other comprehensive income (OCI) positive and OCI negative subgroups. A significance level of 0.05 was set, with P-values below this indicating statistical significance. Statistical comparisons between OBI and OCI-positive and negative groups were performed using the Mann-Whitney U test and Chi-square test.
OBI was found in 32% of IDUs, while OCI was detected in 42% of IDUs, and was present in 53.6% of seropositive individuals. All OBI patients showed a significant increase in all liver function tests, while OCI patients had significant elevations in alanine transaminase and aspartate transaminase values. HIV coinfection was identified in 39.1% and 26.1% of OBI and OCI cases respectively. OBI and OCI coinfection were detected in 31 patients.
Hidden infections such as OBI and OCI remain an overlooked public health issue in Egypt's IDU population. These findings highlight the need for targeted strategies to address these reservoirs of infection and could inform similar approaches in countries with comparable HBV/HCV epidemiology.
本研究旨在确定埃及注射吸毒者(IDU)中隐匿性乙型和丙型肝炎感染的患病率,并确定导致该高危人群感染的关键风险因素。
在这项横断面研究中,对200名埃及注射吸毒者进行了评估。参与者乙肝表面抗原和丙型肝炎病毒(HCV)RNA检测均为阴性,其中包括治疗后实现病毒学持续应答的抗-HCV阳性患者。采用定量聚合酶链反应(PCR)检测血浆和外周血单个核细胞中的HCV RNA,通过巢式PCR鉴定HBV DNA。对隐匿性乙型肝炎感染(OBI)阳性和OBI阴性亚组以及其他综合感染(OCI)阳性和OCI阴性亚组进行比较。设定显著性水平为0.05,P值低于此水平表示具有统计学意义。使用Mann-Whitney U检验和卡方检验对OBI和OCI阳性及阴性组进行统计学比较。
在32%的注射吸毒者中发现了OBI,42%的注射吸毒者检测到OCI,在53.6%的血清学阳性个体中存在OCI。所有OBI患者的所有肝功能检查均显著升高,而OCI患者的丙氨酸转氨酶和天冬氨酸转氨酶值显著升高。分别在39.1%和26.1%的OBI和OCI病例中发现了HIV合并感染。在31例患者中检测到OBI和OCI合并感染。
OBI和OCI等隐匿性感染在埃及注射吸毒者人群中仍然是一个被忽视的公共卫生问题。这些发现凸显了针对这些感染源制定针对性策略的必要性,并可为具有类似HBV/HCV流行病学情况的国家提供类似的方法参考。